Back to Press Releases
AlloPort LLC·Press Release
AlloPort Launches on September 1 Leveling the Playing Field for Accredited Tissue Banks and Expanding Hospital Access to Allografts
Friday, August 21, 2026
San Francisco, CA-August 20, 2006-AlloPort, the first ever real-time, neutral B2B procurement platform purpose-built for AATB-accredited tissue banks and hospital/ASC operating room procurement teams, today announced its planned public launch on September 1, 2026, followed by its industry debut at the American Association of Tissue Banks (AATB) Annual Conference in San Francisco on October 4.
AlloPort was created for the tissue banking industry by tissue banking people. Its leadership and advisory team includes Dr. James Forsell, former Chairman of the American Association of Tissue Banks; Nikki Couloumbis, Founder of Allografts.com; and a veteran team of operators with collectively more than 100 years of healthcare experience. Notably, Dr. Chad Elsner, a Kaiser Permanente Orthopedic Surgeon, is among AlloPort’s first investors and serves on AlloPort’s Board of Advisors.
“AlloPort exists because the tissue banking market needs a credible, industry-aligned procurement platform that expands access without disrupting the trusted role of accredited tissue banks,” says Chris Fure, AlloPort Co-Founder & CEO. “Surgeons need better access to best-fit allografts, procurement managers need faster discovery, and tissue banks deserve a direct, efficient path to operating rooms without surrendering margin to unnecessary intermediaries.”
A Neutral Exchange — Not a Distributor
AlloPort lists inventory and processes orders, but does not hold, store, relabel, or ship allografts. Accredited tissue banks maintain custody, quality control, pricing authority, and fulfillment responsibility. AlloPort routes orders directly to the originating tissue bank for acceptance and fulfillment, while supporting accreditation visibility, state-license gating, lot/UDI traceability, document access, recall readiness, and audit-trail confirmation.
“AlloPort reflects best practices the tissue banking community has advanced for years — license eligibility, traceability, recall readiness, and procurement transparency — now made practical through a single-source procurement solution,” said Dr. James Forsell, AlloPort Co-Founder & CBO (brand) and former AATB Chairman. “It preserves the role of accredited banks while helping procurement managers find the right graft faster.”
AlloPort’s platform centralizes lot-level allograft listings into a single searchable catalog while allowing each tissue bank to continue using its existing inventory management system (demo). The company’s fragmented data aggregation and normalization technology was pioneered at Cisco Systems by AlloPort Co-Founder & CTO Jim Chu, enabling tissue banks to list and maintain real-time allograft availability on AlloPort without replacing or changing their current inventory workflows.
“AlloPort’s technology was designed to remove friction, not add it,” said Chu. “A tissue bank should not have to overhaul its inventory system to participate in a modern procurement network. AlloPort meets banks where they are, normalizes fragmented data, makes available allografts discoverable in real time, and offers side-by-side comparison for the procurement teams who need them.”
Built to Work With the Systems Tissue Banks Already Use
AlloPort’s platform centralizes lot-level allograft listings into a single searchable catalog while allowing each tissue bank to continue using its existing inventory management system. The company’s fragmented data aggregation and normalization technology was pioneered at Cisco Systems by AlloPort Co-Founder & CTO Jim Chu, enabling tissue banks to list and maintain real-time allograft availability on AlloPort without replacing or changing their current inventory workflows.
“AlloPort’s technology was designed to remove friction, not add it,” said Chu. “A tissue bank should not have to overhaul its inventory system to participate in a modern procurement network. AlloPort meets banks where they are, normalizes fragmented data, makes available allografts discoverable in real time, and offers side-by-side comparison for the procurement teams who need them.”
AlloPort was created for the tissue banking industry by tissue banking people. Its leadership and advisory team includes Dr. James Forsell, former Chairman of the American Association of Tissue Banks; Nikki Couloumbis, Founder of Allografts.com; and a veteran team of operators with collectively more than 100 years of healthcare experience. Notably, Dr. Chad Elsner, a Kaiser Permanente Orthopedic Surgeon, is among AlloPort’s first investors and serves on AlloPort’s Board of Advisors.
“AlloPort exists because the tissue banking market needs a credible, industry-aligned procurement platform that expands access without disrupting the trusted role of accredited tissue banks,” says Chris Fure, AlloPort Co-Founder & CEO. “Surgeons need better access to best-fit allografts, procurement managers need faster discovery, and tissue banks deserve a direct, efficient path to operating rooms without surrendering margin to unnecessary intermediaries.”
A Neutral Exchange — Not a Distributor
AlloPort lists inventory and processes orders, but does not hold, store, relabel, or ship allografts. Accredited tissue banks maintain custody, quality control, pricing authority, and fulfillment responsibility. AlloPort routes orders directly to the originating tissue bank for acceptance and fulfillment, while supporting accreditation visibility, state-license gating, lot/UDI traceability, document access, recall readiness, and audit-trail confirmation.
“AlloPort reflects best practices the tissue banking community has advanced for years — license eligibility, traceability, recall readiness, and procurement transparency — now made practical through a single-source procurement solution,” said Dr. James Forsell, AlloPort Co-Founder & CBO (brand) and former AATB Chairman. “It preserves the role of accredited banks while helping procurement managers find the right graft faster.”
AlloPort’s platform centralizes lot-level allograft listings into a single searchable catalog while allowing each tissue bank to continue using its existing inventory management system (demo). The company’s fragmented data aggregation and normalization technology was pioneered at Cisco Systems by AlloPort Co-Founder & CTO Jim Chu, enabling tissue banks to list and maintain real-time allograft availability on AlloPort without replacing or changing their current inventory workflows.
“AlloPort’s technology was designed to remove friction, not add it,” said Chu. “A tissue bank should not have to overhaul its inventory system to participate in a modern procurement network. AlloPort meets banks where they are, normalizes fragmented data, makes available allografts discoverable in real time, and offers side-by-side comparison for the procurement teams who need them.”
Built to Work With the Systems Tissue Banks Already Use
AlloPort’s platform centralizes lot-level allograft listings into a single searchable catalog while allowing each tissue bank to continue using its existing inventory management system. The company’s fragmented data aggregation and normalization technology was pioneered at Cisco Systems by AlloPort Co-Founder & CTO Jim Chu, enabling tissue banks to list and maintain real-time allograft availability on AlloPort without replacing or changing their current inventory workflows.
“AlloPort’s technology was designed to remove friction, not add it,” said Chu. “A tissue bank should not have to overhaul its inventory system to participate in a modern procurement network. AlloPort meets banks where they are, normalizes fragmented data, makes available allografts discoverable in real time, and offers side-by-side comparison for the procurement teams who need them.”